myExtraContent1
myExtraContent5

Jan 2014

7th International VPM Days - presentations online


7th International VPM Days
"Successful Licensing in Translational Product Development"
28.-29. November 2013
im TWINCORE in Hannover


We thank all speakers who accepted our invitation to share their experience with us at the „7th International VPM Days“ in Hannover. Like the years before we are happy to provide the conference presentations online.


Thursday November 28th, 2013


Key Note Lecture:

13.20 – 13.50 Prof. Dr. Dirk Heinz (Helmholtz-Zentrum für Infektionsforschung)
“HZI and DZIF: Vision and mission in translational infection research “


Session 1: Translational Research & Development – Academia Perspective

13.50 – 14.10 Joël Gsponer (Universitätsspital Basel)
“New insights into BCG-therapy for bladder cancer”

14.10 – 14.30 Dr. Nicole van der Wel (Netherlands Cancer Institute)
“Monitoring novel BCG in leprosy lesions”

14.30– 14.50 Prof. Dr. Bodo Plachter (Johannes Gutenberg-Universität Mainz)
“Cytomegalovirus Vaccine – 40 years of development and still on its way”


Session 2: Start-Up Perspective

15.30 – 15.50 Dr. Karsten Fischer (BioMedPartners)
“Caveats of Venture financed Innovation “

15.50 – 16.10 Dr. Axel Polack (TVM Life Science Management GmbH)
“The do’s and don’ts when talking to representatives of Venture Capital Funds “

16.10 – 16.30 Dr. Albrecht Läufer (Corvay GmbH)
“Managing Expectations at Both Ends Before, During and After Negotiating a License Contract“

16.30 – 16.50 Dr. Michael Harder (Corlife GbR)
“corlife 2006-2013 and beyond”

16.50 – 17.10 Dr. Gundel Hager (Aurigon Life Science GmbH)
“Non clinical challenges of novel medicinal products “


Friday November 29th, 2013


Session 3: Pharma Perspective

09.00 – 09.20 Dr. Thomas Hesterkamp (DZIF)
“DZIF-Product Development Unit (PDU)“

09.20 – 09.40 Dr. Stefanie Possekel (Ascenion GmbH)
“What are essential growth factors for a successful academic spin-off?”  

09.40 – 10.00 Dr. Leander Grode (VPM)
“The VPM experience: Successful development and licensing of a gene modified live vaccine for a poverty related disease in a multicultural environment “

10.00 – 10.20 Dr. Paola Rinella (Novartis Pharma GmbH)
“Partnership in biotechnology: what big pharmas want. The vaccine prospective “


Session 4: Legal / IP & Finance

10.50 –11.10 Dr. Jürgen Meier (Vossius & Partner)
“Patenting in the US and in Europe – Strategies post Prometheus and Myriad “

11.10 – 11.30 Dr. Marc Hentz (AMP Therapeutics GmbH )
“Financing Translational Research in Drug Development: Is Germany competitive in funding therapeutics start-ups? “

11.30 – 11.50 Dr. Sven Rohmann (Burrill & Company)
“The do’s and don’ts when talking to representatives of Big Pharma”  

11.50 – 12.10 Dr. Joachim Rautter (Peppermint VenturePartners GmbH
“Financing options for translational product development”  

For additional information please contact:
Vanessa Strüver
Conference Manager
Tel: +49 511 169908-11
Fax: +49 511 169908-29
info@vakzine-manager.de

myExtraContent7
myExtraContent8